bifeprunox + olanzapine

Bifeprunox + olanzapine is a combination of two atypical antipsychotic drugs, each with distinct but complementary mechanisms of action. Bifeprunox acts as a partial agonist at dopamine D2 receptor and serotonin 5-HT1A receptor, functioning as a dopamine system stabilizer by increasing dopamine activity where it is low and decreasing it where it is high. This mechanism aims to treat both positive and negative symptoms of schizophrenia while minimizing side effects such as weight gain or hyperprolactinemia[1][3][5]. Olanzapine, on the other hand, primarily acts as an antagonist at multiple neuronal receptors including dopamine (D1–D4) and serotonin (5HT2A/2C/3/6) receptors, alpha-1 adrenergic receptor, histamine H1 receptor, and muscarinic receptors. It is approved for the treatment of schizophrenia and bipolar disorder in adults and adolescents[2][4][6]. The combination could theoretically provide broad-spectrum antipsychotic efficacy by targeting multiple neurotransmitter systems.

Other names

none